Time to progression is the strongest predictor of outcome in relapsed diffuse large B-cell lymphoma. Second-line treatment with chimeric antigen receptor (CAR) T-cell therapy is recommended for patients with progression within 12 months of first-line chemoimmunotherapy. In patients with late relapse, platinum-based chemotherapy followed by high-dose chemotherapy with autologous stem cell rescue is recommended. In second relapse, CAR T-cell or CD3xCD20 bispecific antibody therapy is recommended in eligible patients. Other treatment options are available for less fit patients. Specific recommendations are made on diagnostic immunohistochemistry, bendamustine use and bridging to CAR T-cell therapy.

在复发弥漫大B细胞淋巴瘤中，进展时间是预后最强的预测因素。对于一线化疗免疫治疗后12个月内进展的患者，推荐采用嵌合抗原受体（CAR）T细胞疗法作为二线治疗；而晚期复发患者，建议先接受铂类化疗，随后进行大剂量化疗联合自体干细胞拯救。若出现二次复发，符合条件的患者可推荐CAR-T细胞疗法或CD3×CD20双特异性抗体治疗，身体状况较差的患者则有其他治疗选择。此外，声明还针对诊断性免疫组化、苯达莫司汀的使用以及桥接至CAR-T细胞治疗等方面给出了具体建议。